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A B S T R A C T
Off-line sample prefractionations applied prior to biomarker discovery proteomics are options to enable
more protein identiﬁcations and detect low-abundance proteins. This work compared ﬁve commercial
methods efﬁciency to raw serum analysis using label-free proteomics. The variability of the protein
quantities determined for each process was similar to the unprefractionated serum. A 49% increase in
protein identiﬁcations and 12.2% of reliable quantiﬁcation were obtained. A 61 times lower limit of
protein quantitation was reached compared to protein concentrations observed in raw serum. The
concentrations of detected proteins were confronted to estimated reference values.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The research of proteomic clinical biomarker was often
undertaken on serum or plasma to highlight biomarkers available
at the systemic level. Indeed clinical trials often collect serum
samples which are sometimes available for ancilary biomarkers
discovery studies. The low-concentration protein range of serum
contains proteins as secretion or tissue leakage products. These are
expected to be more speciﬁc and sensitive potential disease
biomarkers than more abundant proteins [1–3]. The main issue
inherent to the complexity of serum analysis is the limitations of
the technologies used for the discovery analysis: limits of detection
(LOD) and quantiﬁcation (LOQ) and the linear range of response.
Indeed, serum and plasma are very complex biological matrices in
which the protein concentration covers a large dynamic range
higher than 10 orders of magnitude [4]. Currently no high end mass
spectrometer can cover such a large range [5]. Prefractionation
strategies offer an alternative by modifying the original sample
protein distribution inducing shifting/shrinking effects and
allowing proteins initially present at low concentrations to be* Corresponding author.
E-mail address: marie-alice.meuwis@ulg.ac.be (M. -A. Meuwis).
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4.0/).accessible for analysis. Several commercial solutions for sample
prefractionation are proposed to remove abundant proteins which
saturate signal during proteomic analysis and alsofor reaching the
low-abundance proteins [2,6–8]. Of course, off-line or on-line
fractionation steps enhance the number of proteins identiﬁed by
increasing the separation power. But this is at the cost of longer
acquisition times, a modiﬁed limit of quantiﬁcation and a higher
global variability; all due to the additional preprocessing steps
applied [9]. Such multistep strategy is certainly better adapted for
cell lines or animal models complete proteome characterization
without downstream differential analysis [10]. However for
differential analysis and therefore for related clinical proteomics,
a higher number of consistent protein identiﬁcations and more
accurate quantiﬁcation increase the probability to highlight a
signiﬁcant potential biomarker while keeping reasonable data
aquisition time and run length. Therefore, sample preprocessing
steps appear mandatory, but must involve at least a good
repeatability, reasonable cost and manageable processing time
for allowing a medium to high number of clinical sample
preparations.
Among the strategiesavailable are the immuno-afﬁnity depletion
of the abundant proteins as simple IgG and/or albumin or the
depletion of up to the twenty most abundant plasma proteins using
IgY chicken antibodies. These IgY decrease the risk for aspeciﬁc
protein co-depletions potentially occurring with mammalianle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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principle of the equalization technique, utilizing a random synthetic
hexapeptides library cross-linked to micro-beads [16–21] which
actually appears to work according to a general hydrophobic binding
mechanism [4]. The large volume of sample which is required and
the fact that the “equalization mechanism” shrinks the sample
protein concentration dynamic range, can be seen as a problem for
data interpretation after differential proteomic discovery analysis
and furthervalidation of the results. The enrichment of glycoproteins
onlectines mayalsobeusedasanalternative approach.Manystudies
were performed onvarious systems dedicatedto differentialanalysis
[12,22–24]. However, beside works done for protocols testing
[14,20,23,25,26], only one study comparing plasma preprocessing
reproducibility using two commercial kitsunder spin columnformat
and applying a downstream label-free proteomic analysis was
published [27]. Therefore, in this context, the aim of our work was to
compare ﬁve different commercial methods proposed under
disposable spin column format, involving reasonable processing
time and costs and tested using the same serum pool originated from
healthy and diseased individuals. The qualitative and quantitative
results obtained for the ﬁve conditions were compared together as
well as with those obtained with the raw serum analysis. The results
are discussed in the context of the application of the prefractionation
methods on serum before a clinical biomarker discovery study by
label-free proteomics. It can be viewed as a tool to select the most
convenient method to apply on clinical sera before proteomic
analysis.
2. Materials and methods
2.1. Composition of the sample serum pool
All the serum samples of patients were collected with signed
informed consent and with the ethic approval of our university
hospital. Three healthy subjects, ﬁve patients with colorectalFig. 1. Experimental workﬂow detailing the commercial prefractcancer, ﬁve Crohn’s disease and three ulcerative colitis patient
samples were selected to prepare a pool of 5 mL. The serum pool
aliquots of each patient were stored for several years at 80 C
(maximum 5 years) and thawed on ice prior to mixing. This raw
serum pool (RS* pool) was tested for total protein quantitation
using the RC DC kit (BioRad, Inc., Hercule, CA, USA). Aliquots of
suitable volumes were prepared for each protein depletion kit
applications and stored at 80 C until further use.
2.2. Prefractionation of the RS* pool
The methods of depletion tested were: ProteoPrep1 20 Plasma
kit (Sigma St. Louis, USA), under the spin column format, the
ProteoMinerTM (BioRad, Inc., Hercule, CA, USA) designed for 200 mL
of sample volume, IgG & Albumin Spin Trap column (GE Health-
care, USA) and WGA Glycoprotein isolation kit (Thermo-Fisher
Scientiﬁc Inc., USA) with or without prior IgG & Albumin Depletion
Spin Trap (GE Healthcare). Fig. 1 summarizes the workﬂow with
the main sample processing steps applied to the RS* pool before
performing the proteomic analysis.
2.2.1. ProteoMinerTM kit (BioRad Inc., Hercule, CA, USA)
The small capacity kit (designed for 200 mL of sample) was used
for the three technical replicates which were run in parallel. In
brief, a 700 mL volume aliquot of the RS* pool was thawed on ice.
After centrifugation, 3  200 mL of RS* pool were treated in
parallel, as recommended by the manufacturer, and resulted in
three successive elution steps per 200 mL of RS* treated. All three
eluted fractions were pooled together per replicate and stored at
80 C.
2.2.2. ProteoPrep1 20 Plasma kit (Sigma, St. Louis, USA)
This kit was applied as recommended by the manufacturer. We
performed three replicates of process consecutively on the same
column (and on the same day). Brieﬂy, for each process replicateionation and other processing steps applied to the RS* pool.
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in 300 mL of binding buffer provided in the kit. The depletion was
applied twice on 100 mL of ﬁltered and diluted spiked serum pool.
Afterwards, the two depleted fractions collected were pooled
together and concentrated to 100 mL using the VivaSpin (cut-off
5 kDa) included in the kit. The concentrated pool was applied on
column for the second depletion cycle and the ﬁnal depleted
fraction obtained (which was subjected on total to two cycles of
afﬁnity depletion) was further stored at 80 C. Reconditioning of
the afﬁnity column kit was performed according to the manufac-
turer recommendation.
2.2.3. Albumin & IgG Spin Trap column (GE Healthcare, UK Ltd., UK)
An aliquot of RS* pool was thawed on ice and 355 mL of RS* were
diluted with the provided kit binding buffer, to allow for six
replicates (50 mL each) applications. These 6 depletions were run
in parallel using the protocol recommended by the manufacturer.
However, application of the IgG and albumin afﬁnity depletion was
applied twice consecutively for every sample replicate processed.
The three depleted fractions were stored at 80 C until further use
and the three other ones were stored at 4 C and processed using
WGA glycoprotein enrichment on the same day.
2.2.4. WGA Glycoprotein isolation kit (Thermo-Fisher Scientiﬁc, Inc.,
USA)
2.2.4.1. On RS* pool. The three technical replicates performed on
the spiked serum pool were run in parallel. An RS* pool aliquot was
thawed on ice and centrifuged. Only 20 mL per replicate were used
for the kit application as recommended by the manufacturer, usingTable 1
Qualitative and quantitative results summary.
Characteristics ProteoMinerTM Pr
Sample
data
before
MS
analysis
Total starting protein quantity (RCDC on serum
pool) (mg)
13220 10
Volume of RS* pool treated (mL) 200 16
Recovery of total proteins after prefractionation
(mean of 3 replicates  SD, expressed in percent of
total starting quantity treated) (%)
2.3  0.34 1.
Theoretical expected protein quantity recovery
(percentage of starting protein quantity) (%)
0.4–0.7b 1 
Manipulation time for kit application (h) 4 3 
PLGS
2.5 ion
count
tables
derived
data
Quantity of proteins experimentaly identiﬁed and
quantiﬁed by 2D-nanoUPLC–MSE run (mean of
3 process replicates  SD)(ng)
805.29  113.73 14
Number of proteins identiﬁed in the 3 replicates of
process (3R3) (number of proteins identiﬁed and
quantiﬁed in 3R3)
130 (124) 19
Number of proteins identiﬁed and quantiﬁed in
3R3 with individual Qty SD  50%; Qty SD  30%
97; 70 12
Percentage increase obtained compared to RS* pool
for all proteins; for proteins with Qty SD  50%;
with Qty SD  30% (number of proteins gained
compared to RS* pool) (%)
1.5; 4.3; 5.4 49
Number of proteins identiﬁed and quantiﬁed in
3R3 whatever Qty SD, reported to the mean protein
quantity detected (number of prot/ng)
0.154 0.
Number of unique proteins quantiﬁed in all
3 replicates of process (with ﬁlter on Qty SD  50%;
30%)
6 (8; 7) 38
The concentration dynamic range of proteins
identiﬁed and quantiﬁed in 3R3c (with logarithmic
transformation)
3.10 3.
NC, not communicated by manufacturer, NR, not relevant.
a The exact volum treated was 10 mL of diluted RS* pool in PBS such as 20 mg of pro
b Data deduced from previous tests performed in the laboratory (data not shown).
c Concentration dynamic range is the ratio between the highest and the lowest qua
calculated using the three replicates of process performed for both the highest and 
10 logarithmic transformation.200 mg of WGA-lectin beads per replicate.The two steps of elution
were performed using 200 mL elution buffer provided in the kit and
pooled together before storage at 80 C.
2.2.4.2. Albumin and IgG depleted RS* pool. The three technical
replicates of WGA-lectin glycoprotein enrichment performed after
IgG & albumin depletion of the spiked serum pool were run in
parallel. The ﬂow-through (V = 500 mL) of Albumin & IgG depletion
Spin Trap was supplemented with 150 mL of binding buffer. The
next steps of the process were done as recommended by the
manufacturer with the two ﬁnal elutions which were performed
using 200 mL elution buffer provided in the kit. The eluted fractions
were all pooled together before storage at 80 C.
2.3. General experiment strategy considerations
In order to ensure standardization of the digestion and peptides
conditioning at the end of each preparation process, a necessarily
constant quantity of material (=20 mg), was treated. (see Fig. 1). All
the steps of protein clean-up, reduction–alkylation and the ﬁnal
trypsin digestion, were performed in parallel with a standardized
protocol. No other quality control of trypsin digestion was applied
and run in parallel of the samples to simplify the QC of the
experiment. Indeed we considered that the RS* pool replicates
themselves were the QCs of digestion, peptide extraction and MSE
data acquisition and analysis. However, an external QC composed
of entire proteins at known relative quantity ratio and known
concentrations can be run in parallel of the samples as external
digestion QC, but not involving the aspect of matrix of high
complexity as serum.oteoPrep1 20 IgG & albumin IgG &
albumin + WGA
WGA RS*
57 3305 3305 1322 20
 50 50 20 0.3031a
91  0.17 24.47  4.93 7.58  0.52 32.91  3.21 NR
16 <40 NC 100
3 5.5 2.5 0.1
50.43  241.89 1652.35  315.88 653.12  24.78 686.7  75.15 721.1  141.1
1 (178) 134 (122) 127 (117) 130 (128) 128 (126)
7; 83 100; 88 98; 89 31; 21 93; 74
.2; 36.6; 12.2 4.7; 7.5; 18.9 1; 5.4; 20.3 1.5; 66.6;
71.6
NR
123 0.074 0.179 0.186 0.175
 (31; 16) 1 (2; 1) 1 (7; 4) 3 (0; 0) 7 (4; 4)
86 3.52 3.60 3.30 3.78
tein were treated and correspond to only 0.303 mL of undiluted RS*pool.
ntities of the proteins identiﬁed and quantiﬁed in all three replicates (a mean is
the lowest abundant proteins obtained); this ratio value was subjected to base
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the same starting material (for IgG & albumin depletion and
ProteoPrep1 20 kit) to get optimal results. Despite the application
of some depletion cycles twice, the time necessary for all steps
completion stayed inferior to 6 h per sample replicate (see Table 1).
Moreover, these methods at the exception of the ProteoPrep1
20 could be run in parallel reducing again the required sample
preprocessing time and in theory their respective repeatability
variation.
2.4. Protein digestion and preparation for label-free proteomics
After quantitation using the RC DC kit (BioRad, Inc., Hercule, CA,
USA), an aliquot of each fractionated sample replicate and the
diluted RS* pool (20 mg of total proteins) were precipitated in
parallel using 2D-Clean up kit (GE Healthcare, UK). The samples
were all reduced and alkylated as previously described and
digested using porcin recombinant trypsin (Roche, Ltd.,
Switzerland) [28].
Each protein digest was placed in aqueous 0.1% triﬂuoroacetic
acid ﬁnal solution and further puriﬁed using C18 ZipTip high
capacity (Merck Millipore, Billerica, MA, USA). Protein digests were
speed-vacuum dried and reconstituted using 100 mM ammonium
formate solution adjusted to pH 10 at a concentration of 278 ng/mL.
Each injected sample was spiked with a commercial mixture of
protein digest standards originated from non-human biological
material: the MassPREPTM digestion standards (Waters, Corp.,
Milford, USA) at 150 fmol of ADH per sample process replicate. This
commercial standard consists of two standard mixtures (MPDS
Mix 1 and MPDS Mix 2) containing protein digests of yeast alcohol
dehydrogenase (ADH), rabbit glycogen phosphorylase b, bovine
serum albumin, and yeast enolase present at known protein
quantities; allowing therefore to check for relative quantitation of
the samples spiked. Sample injection replicates order on 2D-
nanoUPLC-ESI–MSE (Waters, Corp., Milford, USA) was randomized
and 2.5 mg of total protein digest (in 9 mL) were injected per
sample replicate.
2.5. 2D-nanoUPLC-ESI–MSE system conﬁguration and settings
All eighteen samples (three  ﬁve prefractionated digested
samples and three  RS* pool digested), were injected onto the 2D-
nanoAquity UPLC (Waters, Corp., Milford, USA) coupled online
with the Q-TOF Synapt HDMSTM G2 system (Waters, Corp., Milford,
USA) using ion mobility as supplementary separation. The
conﬁguration of the 2D-nanoUPLC system was a reversed phase
pH 10–reversed phase pH 3 based two dimension separation. The
ﬁrst dimension separation was made on an X-Bridge BEH C18 5 mm
column (300 mm  50 mm). The trap column Symmetry C18 5 mm
(180 mm  20 mm) and analytical column BEH C18 1.7 mm (75 mm
 250 mm) (Waters, Corp., Milford, USA) were used after an online
dilution to lower pH values (minimum been pH 3). The samples
were loaded at 2 mL/min (20 mM ammonium formate solution
adjusted to pH 10) on the ﬁrst column and subsequently eluted in
ﬁve steps (10, 14, 16, 20 and 65% acetonitrile). Each eluted fraction
was desalted on the trap column after a ten times online dilution to
pH 3 and subsequently separated on the analytical column; ﬂow
rate 250 nL/min, solvent A (0.1% formic acid in water) and solvent B
(0.1% formic acid in acetonitrile), linear gradient 0 min, 97% A;
90 min, 65% A. (The total run time of analysis was 5 120 = 600
min).
The mass spectrometer was operated in positive ion mode and
the data acquisition were performed in the 50–1500 m/z range,
with a scan time of 0.6 s and with collision energy voltages set in
independent alternative scanning (MSE) mode. The IMS cell
pressure was set at 2.5 mbar, the variable IMS wave velocityranged from 850 m/s to 1200 m/s and the wave height was 40 V. A
lock mass correction was done using [Glu1]-ﬁbrinopeptide B
([M + 2H]2+: 785.84206 m/z) (Waters Corp., Milford, USA).
2.6. Processing of raw data using ProteinLynx GlobalServer (PLGS 2.5,
Waters Corp., Milford, USA) and analysis of ion account tables
Raw data processing (deconvolution and deisotoping), protein
identiﬁcation and relative quantiﬁcation were all performed using
ProteinLynx Global SERVER (PLGS) v2.5 (Waters Corp., Milford,
USA). The processing parameters were set as follows: the MS TOF
resolution and the chromatographic peak width were both set to
automatic, the low-/elevated-energy detection threshold was set
to 150/15 counts, respectively, the identiﬁcation intensity thresh-
old was 500 counts and the lock mass window at 785.84206 m/z
was set to 0.30 Da.
For the identiﬁcation of the proteins, the UniProt human
database (UniProt release 2011_12-December 14th, 2011) imple-
mented with the sequences of the non-human protein standards
spiked as proteins digests before injection in raw serum (accession
#: P00489,P00924, P02769, P00330), was used. The searched
parameters used were as follows: carbamidomethylation (C) and
oxidation (M) of peptides as ﬁxed and variable modiﬁcations
respectively, two possible trypsin missed cleavages were allowed,
minimum fragment ion matches per peptide of three and
minimum fragment ion matches per protein of seven, minimum
two peptides matches per protein and ﬁnaly a protein false
discovery rate (FDR) for protein was set at maximum 4% (which is
equivalent to a 1% FDR at the peptide level).
Protein and peptides ion account tables were generated during
protein identiﬁcation. The protein quantitation was then based on
calibration using the response factor of the ADH spiked. The
normalization on ADH was also performed using the PLGS vs
2.5 Expression module to control technical variability. The
technical variability was evaluated using comparison between
expected and obtained protein ratios for the different sample
standard Mix MassPREPTM digestion standards Mix 1 or 2 (Waters
Corp., Milford, USA). These were calculated from the expression
analysis tables generated using P00330-ADH normalization to
verify that the process was technically sound and that the
variability of this experiment satisﬁed the one of this label free
technology (maximum 30%) [29]. Ion account tables were used to
extract data concerning the proteins identiﬁed and quantiﬁed in
each replicate done for each samples. The method of quantitation
used for ion account table generation by PLGS vs 2.5, is the “Top 3”
[30]. To enable comparison of different prefractionation methods
applied to the spiked raw serum, we expressed the quantity of each
protein as the percentage of total protein quantity obtained per
replicate run. We calculated each mean protein quantity value
based on the three replicate values for the total protein quantity
and also for each individual protein quantity. We also calculated
the protein concentrations equivalent to the initial quantity (and
volume) of RS* pool treated. This one is refered as the “calculated
raw serum equivalent concentration of protein” and is expressed in
mg/mL. It was obtained by dividing by 100 each protein relative
quantity (obtained using the 3 replicates of process and expressed
in percents), and by multiplying the quotient obtained by a factor.
This factor was deﬁned as the ratio between the quantity of total
protein recovered after the prefractionation and the quantity
analyzed on column. For example, for ProteoPrep1 20 sample:
20.1887 mg/2.5 mg = 8.0755. This last product was further multi-
plied by the mean total protein quantity (obtained with the
3 process replicates and expressed in mg) and divided by the
number of mL of raw serum treated initialy (for ProteoPrep1 20:
0.016 mL). The ratio obtained was therefore different for each kit.
For example, for the ProteoPrep1 20, the ratio is 8.075480 as
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column. For RS* pool, this ratio is 8 (20 mg/2.5 mg). These data were
used to compare the 5 prefractionation methods together and with
the RS* pool results.
The RSD was obtained for the total protein quantity recovery
calculated using each process replicates (=relative Qty SD/mean
relative Qty  100, expressed in %).
All the results data were treated using the Excel tabler.
The Expression Analysis module was used to perform differential
analysis using the three technical replicates done per depletion/
enrichment kit, performing exclusively pairwise comparisons.
Expression analysis was used to verify the spike protein digest of
the standardMix MassPREPTMdigestion standards Mix 1 and 2 ratio.
Normalization was performed on the ADH (P00330). This analysis
was done only considering the proteins identiﬁed and quantiﬁed in
three out of three replicates of process (ﬁlter application: 3R3).
3. Results and discussion
3.1. Total protein quantity obtained for the prefractionated samples
The measured protein concentration of the RS* pool was
66.106  1.890 mg/mL. The total protein quantities and the corre-
sponding sample volumes treated with each method, the expected
theoretical data and the empirical results obtained are summa-
rized in Table 1. The repeatability of each kit applications was
evaluated using the total protein quantity measured just prior to
sample clean-up and it provided a SD < 5%.
3.2. Proteomic results analysis
3.2.1. Data technical quality controls
The MPDS mix protein ratios were calculated using the quantity
of ADH (P00330) spiked amount, while performing expressionFig. 2. (A) Venn diagrams with the poteins identiﬁed per process replicate of each prefr
Comparison illustrated by Venn diagrams of the proteins identiﬁed in 3R3 for the Proteo
From top to bottom the Venn analysis results are shown applying, respectively, no, 50analysis to compare process replicates of each method of serum
preprocessing. All the Mix MassPREPTM digestion standards
proteins showed process replicates SD equal or lower to the
expected 30% [31].
3.2.2. Qualitative and quantitative proteomic results
Table 1 summarizes the main results obtained for each method
of prefractionation and the RS* pool.
3.2.2.1. Total protein recovery. The total protein recovery obtained
after prefractionation and the quantity for each protein identiﬁed
and quantiﬁed are detailed in Table 1. The quantity of each protein
is the mean of the three process replicates  standard deviation
(SD), obtained for each prefractionation method.
3.2.2.2. Individual protein variability. The variability in protein
quantity identiﬁed and quantiﬁed per process replicates is
expressed in ng (see Table 1). The relative standard variations
(RSD) of each sample were lower than 20%. The RS* pool showed in
this experiment the highest RSD at 19.57% counting only for clean-
up, digestion and peptide resolubilisation/extraction yields and the
applied downstream nanoUPLC–MSE step repeatability.The
smallest RSD was obtained with the WGA lectine glycoprotein
enrichment applied after IgG & albumin depletion (RSD = 3.79%).
The RSD of ProteoMinerTM and ProteoPrep1 20 were 14.12% and
16.65%, respectively. The related product “prot20 column” (Sigma)
prefractionation on an off-line FPLC-system combined with label-
free LC–MS/MS analysis provided inter-runs CV assays of 30.9%
[12]. Moreover, the distribution of each protein RSD obtained for
the RS* pool was similar to the one of other pretreated samples
(data not shown). Hakimi et al. using plasma sample and spin
column format of ProteoMinerTM and ProteoPrep1 20, reported a
better reproducibility of process using ProteoMinerTM than using
the ProteoPrep1 20 depletion strategy [27]. On the serum poolactionation method and the RS* pool, all analyzed by label-free MSE proteomics. (B)
Prep1 20, for the ProteoMiner
TM
, IgG & albumin depleted samples and the RS* pool.
% and 30% threshold quantity SD ﬁlter on proteins included.
D. Baiwir et al. / EuPA Open Proteomics 9 (2015) 14–22 19tested in our work, ProteoMinerTM appeared slightly better than
ProteoPrep1 20.
3.2.2.3. Number of different proteins identiﬁed and quantiﬁed
3.2.2.3.1. Data for each method and the RS* pool. Table 1 details the
number of proteins identiﬁed in three replicates out of three (3R3).
The range and the percentage of conserved proteins after the
3R3 ﬁlter application shows the qualitative repeatability of each
method (=prefractionation process and nanoUPLC–MSE). This is
illustrated Fig. 2A with Venn diagrams built with the number of
proteins identiﬁed in each replicate of process (spiked proteins
excluded). The numbers of proteins quantiﬁed and showing a
quantity SD higher than 30% (technical variation of the
instrumental system) and lower than 50% (arbitrary cut-off
value that might be suitable for a discovery phase) are
annotated in the Table 1. As a discovery study should include
some biological replicates to be consistent and as the variability
associated to biological replicates is certainly higher than the
technical one, we included an analysis of the data after applying
this 50% cut-off for quantity SD (%). This indicated the number of
proteins that might be of true value for consistent results analysis
after sample preprocessing. The 30% threshold ﬁlter corresponding
to the technical variability of the instrumental system used in this
experiment could be considered as too stringent.
3.2.2.3.2. Comparison of the results obtained after the
prefarctionations to the RS* Pool. Fig. 2 B shows Venn diagrams
comparing three selected methods together and with the RS* pool.
The comparison of the six protein lists identiﬁed in 3R3, without
any quantity SD ﬁlter, can be downloaded as Supplementary data
Table 1. In the analysis including all the proteins whatever quantity
SD obtained, only 71 proteins were found common to the
6 conditions compared. The maximum number of “unique
proteins”, identiﬁed solely in one prefractionation method, with
3R3 ﬁlter application and with a quantity SD lower to the two
thresholds are also reported in Table 1. The numbers of “unique
proteins”indicate the advantage of one method over the others and
mostly over no prefractionation (RS* pool sample). ProteoPrep1
20 provided the highest number of “ unique proteins” whateverFig. 3. The six ranges of calculated raw serum equivalent protein concentration obtai
prefractionation and for the RS* pool sample.
Protein with quantity SD  30% (ﬁlled label: *); Quantity SD > 30% (empty label: )
The lowest abundant proteins reliably quantiﬁed in each sample (Qty SD  30%) are K1
forProteoPrep1 20; K1C28 (0.297  0.514 mg/mL) for IgG & albumin; K1C28 (0.052  0.0
(0.288  0.500 mg/mL) for RS* pool.quantity SD ﬁlter is applied. In addition, ProteoPrep1 20 process
enabled a 49% increase in number of proteins identiﬁed compared
to the RS* pool (in 3R3; no Qty SD ﬁlter). But when analyzing the
number of proteins with a suitable quantity SD, the gain of 36.6 %
obtained for 50% Qty SD dropped to 12.2%, when using the
technical 30% threshold. At this level of stringency, the Albumin &
IgG Depletion Spin Trap kit or the combination of IgG & albumin
depletion prior to WGA enrichment appeared to be slightly
superior with a gain of 18.9% and 20.3%, respectively over the RS*
pool. The apparent increases observed for some of the
prefractionation kits used must be nuanced depending on the
stringency of analysis. Altogether, ProteoPrep1 20 enrichment
provided the highest advantage, regarding the quantity/volume
ratio of raw biological material needed for the kit application and
the number of proteins signiﬁcantly identiﬁed and quantiﬁed. All
the other prefractionation methods tested regarding these criteria
did not provided better results than the RS* pool.
3.2.3. The most abundant proteins and their depletion efﬁciencies
3.2.3.1. The 20 most abundant protein families
analysis. Supplementary data Table 2 details all the proteins
and protein families targeted by the ProteoPrep1 20 plasma kit
(according to information provided by the manufacturer data
sheet). The data provided to facilitate comparison of kit efﬁciencies
are the relative quantities (% of the total quantity of protein
detected and quantiﬁed for each condition). When summing the
relative protein quantity percentages of the IgG family members
identiﬁed (Prot.entry and Prot.Acc # with ** in Supplementary data
Table 2), the ProteoPrep1 20 method showed the lowest total
relative quantity, which indicates their more efﬁcient depletion
with this kit. The calculated protein concentrations, equivalent to
raw serum (mg/mL) and the corresponding SD are also
communicated for each sample. But, not all the most abundant
proteins pointed showed an individual quantity SD < 30%.
3.2.3.2. The efﬁciency of albumin (HSA) depletion. The method that
provided the best results concerning HSA depletion was the
combination of IgG & albumin depletion with downstream WGAned for the proteins identiﬁed and quantiﬁed in 3R3 (mg/mL) for the methods of
C25 (0.018  0.031 mg/mL) for ProteoMinerTM; ACTH (5.84 103 10.13 103mg/mL)
89 mg/mL) for IgG & albumin + WGA; KRT15 (0.227  0.394 mg/mL) for WGA; HBD
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percentage. The second best was WGA enrichment and the
worst was ProteoMinerTM with results closer to these of RS*
pool. Knowing that HSA is present in serum at approximately 75%
of total protein quantity [32], the low percentage in RS* pool (9.15%
of HSA quantiﬁed) illustrated the compression of the protein
concentration dynamic range obtained. This was however
expected using this proteomic technology and these settings,
potentially involving also suppression effects well known with
electrospray ionization (ESI) and the fact that the quantitation of
analytes with this technology is concentration dependent [33].
However, one must keep in mind that very highly concentrated
proteins (as HSA) and therefore the most abundant ones, could be
saturating and not be correctly quantiﬁed. Importantly, HSA
showed, only for RS*pool, ProteominerTM and WGA enrichment,
quantity SD lower to 30%.
3.2.4. The protein concentration dynamic ranges and the abilities to
measure low-abundance proteins in serum
3.2.4.1. Protein concentration dynamic range. Table 1 provides the
dynamic ranges of protein concentrations observed (with base
10 logarithmic transformation) for the six conditions analyzed.
Fig. 3 shows for every method tested, the distribution of the
proteins identiﬁed and quantiﬁed and ranked in decreasing order
of calculated equivalent to raw serum concentrations (using a base
10 logarithmic scale). The largest distribution in term of protein
concentrations was obtained using the ProteoPrep1 20 and second
best was the RS* pool itself. The smallest range observed was
obtained after equalization with ProteoMinerTM which might be
obvious considering the theoretical principle of this kit. This is in
opposition with what was reported previously using similar
workﬂows: DIA and label-free strategy [27]. In this work,
ProteoMinerTM application on plasma enabled detection of
proteins within a 5 orders logarithmic range of protein
concentrations. This demonstrates again the shrinking effect of
this strategy when applied on serum matrix, as reported previously
[21,34]. But also highligh the difference of results obtained when
using plasma or serum. Fig. 3 shows that the maximum gain in
protein identiﬁcations number (49%) obtained with ProteoPrep1
20, were proteins lying within medium values of the protein
relative quantiﬁcation range. The ProteoMinerTM curve obtained
was not as ﬂat as could be expected after equalization. But the
results obtained for the 6 conditions when considering only
individual proteins with quantity SD  30%, (illustrated using the
ﬁled label on the graph), allowed the same conclusions, but with a
dynamic range 0.5–1 order shorter. Supplementary data
Table 3 illustrates also the deformation in the proteins
concentration dynamic range observed for the six conditions
compared. Some proteins were selected at different representative
relative quantities and distributed within the range observed in the
RS* pool. Their corresponding calculated equivalent to raw serum
protein concentrations are provided, as well as known
concentrations measured in serum [35], plasma concentration
observed [1,36,37] or estimated [38]. The ranking of abundances
were affected when using prefractionation and some proteins
showed quantity below the lower limit of quantitation (LLOQ) of
the method. The deformation observed might be driven by
compression effects and also by some truncations in the
concentration range due to the depletion of some speciﬁc
proteins, also visible in Fig. 3. For example the vitamin D
binding protein (VTDP- P02774), not related to cell structure but
to the active analyte of vitamin D transport, was not expected to be
within the low concentration range in serum. Its concentration
ranges from 193 to 4350 mg/L in serum of healthy individuals (all
phenotypes considered) [35]. But, some values obtained for someof the kits tested (see Supplementary data Table 3) are very
different and cannot all be reliably considered (because of Qty
SD > 30 %). For example in ProteoMinerTM, it is detected at only 0.6%
of the value found for the RS* pool sample. But binding of proteins
with ProteoMinerTM has been shown to be driven by non speciﬁc
hydrophobicity rather than by the hexapeptide afﬁnity. In this
mechanism the hydrophobicity of each protein present in the
complex mixture drives their own respective binding and
depletion [4]. However, abundant hydrophilic proteins as IgG or
apolipoprotein A1 (ApoA1) were merely depleted efﬁciently with
this method, which was also observed in this serum data set (see
Supplementary data Table 2). Importantly, some proteins were
quantiﬁed for some samples only with a quantity SD higher to
30 or 50% and might or should therefore not be considered as
reliably quantiﬁed.
3.2.4.2. The ability to reach low-abundance proteins. To evaluate if
the prefractionations tested enabled the analysis of proteins
present at low concentrations in serum (the deep proteome), one
should compare the proteins quantiﬁed as lowest ones in each
sample to their level in serum determined by other techniques. But
most of these serum protein levels are not available in literature,
despite that valid reference measurements or estimations might be
available for plasma [36]. Therefore, no reference could be used to
compare the gain in low-abundance serum proteins reached by
these kits. However, we analyzed for each process replicate, the
lowest quantity detected. All the kits provided similar results with
no signiﬁcant difference (Mann–Withney test, P value > 0.05) to
these obtained with the RS* pool sample (lowest single replicate
value = 0.010 ng, with a mean value over the triplicates of
0.022  0.027 ng). This was due to the main limitations of the
experimental design, where a constant quantity of total protein
digest was loaded on column, in addition to the lower limit of
quantiﬁcation (LLOQ) of the technology itself. However, when
considering the results expressed in terms of calculated raw serum
equivalent protein concentrations, and with quantity SD < 30%
ﬁlter, the lowest values were found for Dermicin (P81605). Its
mean concentration is 0.067 mg/mL  21% in the ProteoPrep1
20 sample. The ratio between the lowest protein quantities
obtained in the RS* pool and the ProteoPrep1 20 is 49 (61 when
considering the proteins with quantity SD  30%). The three
methods enabling to measure proteins present at lower
equivalent raw serum concentrations compared to RS* pool
were IgG & albumin depletion coupled with WGA enrichment,
ProteoMinerTM and ProteoPrep1 20, showing itself the lowest
value. Hence, despite that the comparison of our results with
literature serum references was not always possible, we could
conclude that in our experiment and data set, ProteoPrep1
20 enabled the lowest calculated equivalent raw serum
concentrations of protein, with 49–61 times lower values than
these obtained with the RS* pool.
3.2.5. Comparison of the results of ProteoPrep1 20 treated sample to
reference concentrations of proteins
The list of proteins identiﬁed and quantiﬁed in the ProteoPrep1
20 sample is available as Supplementary data Table 4. This table
provides the quantity of each protein and SD (both expressed in
percentage of total protein quantity detected) and each protein
Quantity SD (in %). The calculated ProteoPrep1 20 depleted serum
concentration (mg/mL) of proteins equivalent to the initial raw
serum and also, some known reference concentrations of these
proteins taken from the “high conﬁdence plasma proteome
reference set” are reported [38]. These concentration references
in plasma or serum are provided for ranking comparison of the
proteins found in a non depleted serum or plasma and identiﬁed
after ProteoPrep1 20 serum depletion. Regarding the proteins
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38 proteins (in bold) were identiﬁed only after using this depletion
method (=“unique proteins”). Compared to the 1929 non canonical
sequences reported by Farrah et al., 45 proteins were identiﬁed
only in our analysis. These are not all related to the complement
activation and the coagulation process as would be expected in
serum compared to plasma. These proteins might also be related to
the disease state of the patient sera included in our RS* pool.
3.3. General conclusions
The ﬁve methods tested together with label-free proteomic
analysis on a 2D-nanoUPLC–MSE Synapt G2 system showed
acceptable repeatabilities, similar to the one obtained for the
RS* pool sample analysis. All ﬁve methods showed equivalent
performances regarding total protein quantity recovery. Surpris-
ingly, the RS* pool already provided very interesting results with
this system settings, which illustrates its power in terms of
peptides and ions separations and proteins identiﬁcations, as well
as relative quantiﬁcation. But, some of the prefractionations tested
did not add much information over the raw serum analysis. This is
worth knowing before spending time, energy and resources on
precious clinical samples prefractionation. In summary, in our
hands, the ProteoPrep1 20 which is the only fully re-usable kit
present the following advantages. First, it requires the lowest
volume or quantity of precious clinical sera. Second it enables the
maximum number of protein identiﬁcations increase (49%)
compared to the RS* pool with the highest number of unique
proteins. However other depletion protocols might even be more
valuable if very stringent Qty SD threshold have to be applied.
These involves IgG & albumin depletion strategy. Nevertheless, the
third main advantage of the ProteoPrep1 20 relies on the
possibility to reach up to 61 times lower protein concentration
values compared to non depleted serum which are low abudance
protein not always detectable for other kits.
But this depletion kit is not perfect as it is expensive and time
consuming (two successive cycle of depletions were necessary to
reach the purity obtained in this work). This antibody afﬁnity
capture spin column is a reusable format and despite the warranty
that one hundred applications might be done without losing
depletion efﬁciency, bias in sample processing for a clinical sample
set due to the order of samples prefractionation could still occur.
Hence, the order of samples should always be randomized,
shufﬂing diseases and controls (and likely QC) to minimize the
potential effect as such a bias risk. Moreover, potential cross-
contaminations remain possible, even if careful reconditioning of
the spin column is performed between the depletion cycles.
Altogether, albeit not perfect, ProteoPrep1 20 appeared in this
experimental design and data set to be a suitable compromise for
application as off-line serum samples prefractionation strategy.
The results of a differential label-free proteomic analysis for
clinical biomarkers discovery phase would proﬁt from this type of
prefractionation as long as results are analyzed knowing the
technical repeatability of the glogal strategy.
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